Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab

Lucia Moiola; Alessandra Mandelli; Maciej Tarkowski; Annamaria Finardi; Arianna Gabrieli; Chiara Zanetta; Vittorio Viti; Irene Gattuso; Federica Esposito; Rosetta Pedotti; Erwan Muros‐Le Rouzic; Catarina Raposo; Maria A. Rocca; Massimo Locatelli; Chiara Bonini; Roberto Furlan; Agostino Riva; Massimo Filippi

doi:10.1007/s00415-025-13027-x

Back

Recall vaccination increases detectable B-cell reactivity in persons with multiple sclerosis treated with ocrelizumab

Article 2025 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2021

Serological response to SARS-CoV-2 vaccination in multiple sclerosis patients treated with fingolimod or ocrelizumab: an initial real-life experience

Sara Guerrieri, Serena Marita Lazzarin, Chiara Zanetta, Agostino Nozzolillo, Massimo Filippi, Lucia Moiola

Letter2021

COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?

Stefano Gelibter, Mario Orrico, Massimo Filippi, Lucia Moiola

Letter2024

Ocrelizumab-associated enteritis in patients with multiple sclerosis: an emerging safety issue

Vittorio Viti, Chiara Zanetta, Ruggero Capra, Andrea Municchi, Maria A. Rocca, Massimo Filippi

Article2021

Uptake of influenza vaccination among persons with inflammatory bowel disease, multiple sclerosis or rheumatoid arthritis: a population-based matched cohort study

Ruth Ann Marrie, Randy Walld, James M. Bolton, Jitender Sareen, Scott Burton Patten, Alexander Singer, Lisa M. Lix, Carol Hitchon, James Marriott, Renée El‐Gabalawy, Alan Katz, John D. Fisk, Çharles N. Bernstein

Article2018

The prevalence of anxiety and associated factors in persons with multiple sclerosis

Tram Pham, Nathalie Jetté, Andrew G. M. Bulloch, Jodie Burton, Samuel Wiebe, Scott Burton Patten